Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5309084 | 0.89 | HSD11B1 (0.47) | TSHRATMALDH1A1L3MBTL1MAPT | |
| SCHEMBL11088941 | 0.84 | ALDH1A1 (0.53) | TSHRATMALDH1A1L3MBTL1MAPT | |
| SCHEMBL21516127 | 0.82 | GABBR2 (0.50) | MAPTLMNAMAPK1CYP2C19KMT2A | |
| SCHEMBL7537470 | 0.82 | GABBR2 (0.50) | MAPTLMNAMAPK1CYP2C19KMT2A | |
| SCHEMBL28053808 | 0.82 | MAPT (0.48) | TSHRALDH1A1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL28053810 | 0.80 | TDP1 (0.55) | ALDH1A1L3MBTL1MAPTSMN1; SMN2LMNA | |
| SCHEMBL27556646 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL6136571 | 0.79 | CYP2D6 (0.50) | TSHRALDH1A1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL31390336 | 0.78 | ALDH1A1 (0.48) | TSHRATMALDH1A1L3MBTL1MAPT | |
| SCHEMBL6200667 | 0.78 | TSHR (0.63) | TSHRATMALDH1A1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103459467-B | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO.,INC. (JP) | 2016-04-06 | — | — | CN | claimed |
| CN-103459467-B | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO.,INC. (JP) | 2016-04-06 | — | — | CN | disclosed |
| CN-103459467-A | Polybenzoxazole resin and precursor thereof | MITSUBISHI GAS CHEMICAL CO | 2013-12-18 | — | — | CN | disclosed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1928827-B1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217073-B2 | Pyrrole derivatives as therapeutic compounds | MYREXIS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7714022-B2 | Pyrrole derivatives as therapeutic compounds | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1928827-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008031034-A2 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038684-A2 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | MYRIAD GENETICS, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065241-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | TSHR 4151/4885ATM 3896/4885ALDH1A1 2759/4885 |
| US-20080249158-A1 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS | APP, PSEN2, PSEN1 | TSHR 3526/4885ATM 2274/4885ALDH1A1 4389/4885 |
| US-20090253768-A1 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS | NLN, SLC18A2, GOLT1B | TSHR 4151/4885ATM 3896/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.